Abstracts tagged "COVID-19"

Abstract Number: 0011 • ACR Convergence 2020
Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
David Simon¹, Koray Tascilar¹, Gerhard Krönke², Arnd Kleyer¹, Mario Zaiss³, Franz Heppt⁴, Christine Meder⁴, Raja Atreya⁵, Entcho Klenske⁵, Peter Dietrich⁵, Abdullah Abdullah⁵, Thorsten Kliem⁵, Giulia Corte⁶, Harriet Morf³, Moritz Leppkes⁵, Andreas Kremer⁵, Andreas Ramming³, Milena Pachowsky⁷, Florian Schuch⁸, Monika Ronneberger⁹, Stefan Kleinert¹⁰, Clara Maier¹¹, Axel Hueber¹², Karin Manger¹³, Bernhard Manger³, Carola Berking⁴, Matthias Tenbusch¹¹, Klaus Überla¹¹, Michael Sticherling³, Markus Neurath⁵ and Georg Schett¹⁴, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Georgia, ³Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Dermatology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Internal Medicine 1, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Gibraltar, ⁷Department of Orthopedic and Trauma Surgery, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Rheumatology Clinical Practice Erlangen, Erlangen, Ghana, ⁹Rheumatology Clinical Practice Erlangen, Erlangen, Germany, ¹⁰Rheumatology-Nephrology Practice, Erlangen, Germany, ¹¹Institute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ¹²Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, ¹³Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…
Abstract Number: 0413 • ACR Convergence 2020
Coronavirus Infection and Vasculitis: Identifying Associations Mining the Biomedical Literature
Alicia Rodriguez Pla¹ and Rodrigo Cartin-Ceba², ¹Rheumatology. Mayo Clinic Arizona, Scottsdale, ²Pulmonary. Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Based on recent publications suggesting an association between COVID-19 and vascular inflammation, our aim was to explore new associations between coronavirus infections and vasculitis…
Abstract Number: 0545 • ACR Convergence 2020
The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Case Series
Naomi Serling-Boyd¹, Amir Mohareb², Arthur Kim², Emily Hyle² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: The use of immunosuppressive medications in patients with a history of hepatitis B virus (HBV) infection is associated with an increased risk of HBV…
Abstract Number: 0629 • ACR Convergence 2020
COVID-19 Among Patients with Immune-mediated Inflammatory Diseases: A Descriptive Study
Jesús Loarce-Martos¹, Antía García-Fernández¹, Fernando López-Gutiérrez¹, Veronica Garcia², Laura Calvo-Sanz¹, Ivan Del Bosque-Granero², Cristina Pijoan-Moratalla¹, Lourdes Villalobos-Sánchez³, Boris Blanco-Cáceres¹, Javier Bachiller-Corral¹ and Mónica Vázquez¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMID) have a higher risk of infections related to their disease, comorbidities or immunosuppressive treatments, but recent studies addressing…
Abstract Number: 1267 • ACR Convergence 2020
Perceived Stress During the COVID-19 Pandemic Independently Associates with Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)
Sarah Patterson¹, Laura Trupin², Kimberly DeQuattro¹, Cristina Lanata¹, Maria Dall'Era³, Jinoos Yazdany² and Patricia Katz², ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Causes and risk factors for variations in SLE disease activity and symptom severity are incompletely understood. Prior studies suggest a link between stressful life…
Abstract Number: 1585 • ACR Convergence 2020
Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in an Academic Rheumatology Practice During the COVID-19 Pandemic
Julie Thomas¹, Dorota Lebiedz-Odrobina¹, Kyle Register¹, Francesca Ferrara¹, Danielle Barlow¹, Alicia Riddle¹ and Karla Miller², ¹University of Utah, Salt Lake City, UT, ²Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic created an urgent need for access to care while preserving patient safety through social distancing. Prior to the pandemic, patients were…
Abstract Number: 0012 • ACR Convergence 2020
Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
Kristin Wipfler¹, Yomei Shaw², Teresa Simon³, Adam Cornish¹, Bryant England⁴, Alexis Ogdie⁵, Patricia Katz⁶ and Kaleb Michaud⁴, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, East Lansing, MI, ³Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, Novato, CA
Background/Purpose: Patients with rheumatic diseases such as RA and lupus have increased risk of infection and are treated with medications that may increase this risk…
Abstract Number: 0429 • ACR Convergence 2020
Prothrombotic Antiphospholipid Antibodies in COVID-19
Yu Zuo¹, Shanea Estes², Alex Ghandi³, Srilakshmi Yalavarthi³, Ramadan Ali³, Shi Hui³, Gautam Sule³, Kelsey Gockman³, Jacqueline Madison³, Melanie Zuo³, Wrenn Woodard³, Sean Lezak³, Njira Lugogo³, Yogendra Kanthi⁴ and Jason Knight¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, ⁴Division of Cardiovascular Medicine, Ann Arbor
Background/Purpose: Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombosis of arteries and veins. At the same time, COVID-19 lung histopathology has…
Abstract Number: 0578 • ACR Convergence 2020
Going Digital Due to COVID 19 Crisis: A Rapid Reorganisation of Medication Clinics
Rian Penford¹, Angela Reith¹, Elaine Wren¹ and Kirsten Mackay¹, ¹Torbay and South Devon NHS Foundation Trust, Torquay, United Kingdom
Background/Purpose: Until the COVID 19 crisis we initiated DMARD(s) and Biologic therapies using shared medical clinics. More than 30 patients could seen per week, with…
Abstract Number: 0633 • ACR Convergence 2020
Vitamin D Serum Status in a Cohort of COVID-19 Patients
Alberto Sulli¹, Emanuele Gotelli¹, Sabrina Paolino¹, Andrea Casabella¹, Carmen Pizzorni¹, Elisa Alessandri¹, Vanessa Smith² and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy, ²Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium
Background/Purpose: Vitamin D serum levels have been inversely associated with risk of pulmonary infections and autoimmune inflammatory disease activity and severity [1,2]. A possible role…
Abstract Number: 1274 • ACR Convergence 2020
COVID-19 in Patients with Systemic Lupus Erythematosus
Ruth Fernandez-Ruiz¹, Mala Masson¹, Mimi Kim², Benjamin Myers³, Rebecca Haberman⁴, Jose Scher⁴, Rochelle Castillo⁴, Allison Guttmann¹, Philip Carlucci¹, Kristina Deonaraine¹, Michael Golpanian⁵, Kimberly Robins¹, Miao Chang¹, H. Michael Belmont⁶, Jill Buyon⁷, Ashira Blazer⁶, Amit Saxena⁸ and Peter Izmirly⁹, ¹New York University School of Medicine, New York, ²Albert Einstein College of Medicine, Bronx, ³Cornell University, Ithica, NY, ⁴NYU School of Medicine, New York City, ⁵New York University, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷Department of Medicine, NYU School of Medicine, New York, NY, ⁸NYU School of Medicine, New York, ⁹Department of Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) represent a unique population in considering risk for coronavirus disease 2019 (COVID-19) with biologic, genetic, demographic, clinical and…
Abstract Number: 1604 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on Rheumatology Practice: A Study in 15 Arab Countries
Nelly Ziade¹, Ihsane Hmamouchi², Lina El Kibbi³, Nizar Abdulateef⁴, Hussein Halabi⁵, Fatemah Abutiban⁶, Wafa Hamdi⁷, Manal el Rakawi⁸, Mervat Eissa⁹ and Basel Masri¹⁰, ¹Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ²Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, ³Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ⁴Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq, ⁵King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁶Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah hospital, State of Kuwait, Jahra, Kuwait, ⁷Department of Rheumatology, Kassab Institute of orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia, Tunis, Tunisia, ⁸Departement of Rheumatology, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, Blida, Algeria, ⁹Rheumatology Department, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Jordan Hospital, Amman, Jordan, Amman, Jordan
Background/Purpose: To date, information about the impact of the Coronavirus Disease (COVID-19) pandemic on rheumatology practice and on rheumatologists is limited.The primary objective of the…
Abstract Number: 0013 • ACR Convergence 2020
Colchicine to Weather the Storm in Hospitalized Patients with COVID-19
Luigi Brunetti¹, Oumou Diawara¹, Andrew Tsai², Bonnie Firestein³, Ronald Nahass⁴, George Poiani⁵ and Naomi Schlesinger⁶, ¹Rutgers Ernest Mario School of Pharmacy, piscataway, NJ, ²Center of Excellence in Pharmaceutical Translational Research and Education, piscataway, NJ, ³Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, piscataway, NJ, ⁴Robert Wood Johnson University Hospital Somerset, somerset, NJ, ⁵Rutgers Robert Wood Johnson Medical School, somerset, NJ, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) infection, is a global pandemic causing havoc. There is a knowledge gap regarding…
Abstract Number: 0430 • ACR Convergence 2020
Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network
Kristin D'Silva¹, April Jorge¹, Na Lu², Yuqing Zhang³, Zachary Wallace⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Whether patients living with systemic autoimmune rheumatic diseases (SARDs) suffer from more severe complications of Coronavirus Disease 2019 (COVID-19) infection remains unknown.Methods: We conducted…
Abstract Number: 0587 • ACR Convergence 2020
Barriers to Rheumatologic Care and Antimalarial Refills Among a Cohort of Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Alfredo Aguirre¹, Laura Trupin¹, Sarah Patterson², Kimberly DeQuattro², Patricia Katz³, Cristina Lanata², Stephanie Rush¹, Lindsey Criswell⁴, Maria Dall'Era⁵ and Jinoos Yazdany¹, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, Novato, CA, ⁴Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: The pandemic of coronavirus disease 19 (COVID-19) has led to widespread disruptions across the spectrum of healthcare. We sought to investigate barriers to medical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].